Dx dialogues: VMAT2 inhibitors and future treatments for tardive dyskinesia
Domenick Sportelli, DO, talks about VMAT2 inhibitors and other treatments being investigated for the treatment of tardive dyskinesia.
Up Next
Dx dialogues: the challenges of treating tardive dyskinesia the "old-fashioned way"
Dx dialogues: why early intervention is critical in managing tardive dyskinesia
Dx dialogues: pharmacologic advances for the treatment and management of schizophrenia
Dx dialogues: novel approaches in development for the treatment of AD
Treating tardive dyskinesia
5 tips for finding the best treatment for tardive dyskinesia
Dx dialogues: considerations when deciding whether to initiate pharmacologic interventions for patients with AD
Dx dialogues: stigma surrounding LAI use for schizophrenia and the importance of patient education
Dx dialogues: identifying patients who might benefit from an LAI for schizophrenia
5 complications of living with tardive dyskinesia
